Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Purchased by Amalgamated Bank

Amalgamated Bank raised its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 1.4% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 74,442 shares of the medical research company's stock after buying an additional 995 shares during the quarter. Amalgamated Bank's holdings in Thermo Fisher Scientific were worth $37,042,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently modified their holdings of the company. LaFleur & Godfrey LLC increased its holdings in shares of Thermo Fisher Scientific by 9.1% during the 4th quarter. LaFleur & Godfrey LLC now owns 29,767 shares of the medical research company's stock worth $15,486,000 after buying an additional 2,488 shares during the last quarter. Brighton Jones LLC grew its position in Thermo Fisher Scientific by 28.9% during the fourth quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company's stock valued at $2,293,000 after acquiring an additional 988 shares during the period. Revolve Wealth Partners LLC increased its stake in Thermo Fisher Scientific by 4.2% during the fourth quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company's stock worth $255,000 after acquiring an additional 20 shares during the last quarter. Bank Pictet & Cie Europe AG lifted its stake in shares of Thermo Fisher Scientific by 0.3% in the 4th quarter. Bank Pictet & Cie Europe AG now owns 153,157 shares of the medical research company's stock valued at $79,677,000 after purchasing an additional 461 shares in the last quarter. Finally, SVB Wealth LLC purchased a new stake in shares of Thermo Fisher Scientific during the 4th quarter worth about $3,545,000. Institutional investors and hedge funds own 89.23% of the company's stock.

Insiders Place Their Bets

In other news, EVP Gianluca Pettiti sold 300 shares of the business's stock in a transaction that occurred on Monday, April 28th. The stock was sold at an average price of $429.93, for a total transaction of $128,979.00. Following the completion of the transaction, the executive vice president now directly owns 23,167 shares in the company, valued at approximately $9,960,188.31. The trade was a 1.28% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. 0.33% of the stock is owned by insiders.

Analyst Ratings Changes

TMO has been the topic of several research reports. Stifel Nicolaus reduced their price target on shares of Thermo Fisher Scientific from $665.00 to $620.00 and set a "buy" rating on the stock in a research report on Thursday, April 24th. Argus reduced their target price on shares of Thermo Fisher Scientific from $620.00 to $470.00 and set a "buy" rating on the stock in a report on Tuesday, April 29th. Evercore ISI lowered their price target on Thermo Fisher Scientific from $585.00 to $500.00 and set an "outperform" rating for the company in a report on Thursday, April 24th. Wells Fargo & Company reduced their price objective on Thermo Fisher Scientific from $580.00 to $570.00 and set an "overweight" rating on the stock in a research note on Thursday, April 24th. Finally, Wall Street Zen upgraded Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a research note on Wednesday, May 21st. Four research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $604.05.

Thermo Fisher Scientific Stock Down 1.1%

NYSE:TMO opened at $407.67 on Monday. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.38 and a current ratio of 1.77. The company has a market capitalization of $153.89 billion, a price-to-earnings ratio of 23.91, a price-to-earnings-growth ratio of 2.17 and a beta of 0.78. Thermo Fisher Scientific Inc. has a one year low of $385.46 and a one year high of $627.88. The stock has a 50-day simple moving average of $409.74 and a 200 day simple moving average of $482.94.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share for the quarter, beating analysts' consensus estimates of $5.10 by $0.05. Thermo Fisher Scientific had a return on equity of 17.15% and a net margin of 15.19%. The business had revenue of $10.36 billion during the quarter, compared to the consensus estimate of $10.23 billion. During the same period in the previous year, the business earned $5.11 EPS. The business's quarterly revenue was up .2% on a year-over-year basis. Sell-side analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, July 15th. Stockholders of record on Friday, June 13th will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 0.42%. The ex-dividend date is Friday, June 13th. Thermo Fisher Scientific's dividend payout ratio (DPR) is 10.09%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.